Anticancer agents: VTA or VDA

Current Bioactive Compounds

Volumn 5, Issue 1, 2009, Pages 79-97

  Sebahar, Paul R ^a   Willardsen, J Adam ^a   Anderson, Mark B ^a  

^a Myriad Pharmaceuticals   (United States)

Author keywords

Angiogenesis; Inhibitor; Oncology; Tubulin; Vascular disrupting; Vascular targeting

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AS 203; BATABULIN; CEDIRANIB; COLCHICINE; COMBRETASTATIN A4 PHOSPHATE; CYT 997; DASATINIB; DOCETAXEL; EPOTHILONE B; ERLOTINIB; GEFITINIB; IMATINIB; IXABEPILONE; LAPATINIB; LAROTAXEL; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NAVELBINE; NPI 2358; ONVOCIN; OPAXIO; PACLITAXEL; PACLITAXEL POLIGLUMEX; SAGOPILONE; T 27; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VINBLASTINE SULFATE; VINCRISTINE SULFATE; VINDESINE; VINFLUNINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR VASCULARIZATION;

EID: 65649149425     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340709787580919     Document Type: Review

References (143)

1. Dome, B.; Hendrix, M. J. C.; Paku, S.; Tovari, J.; Timar, J. (2007) Alternative Vascularization Mechanisms in Cancer: Pathology and Therapeutic Implications. Am. J. Pathol., 170 (1), 1-15.
2. Liu, J. F.; Wilson, C. J.; Ye, P.; Sprague, K.; Sargent, K.; Si, Y.; Beletsky, G.; Yohannes, D.; Ng, S. C. (2006) Privileged structure-based quinazolinone natural product-templated libraries: Identification of novel tubulin polymerization inhibitors. Bioorg, Med, Chem, Lett., 16 (3), 686-90.
3. Ehrlich, P. (1909) Dtsch. Chem. Ges., 42, 17.
4. Gund, P. (1977) Prog. Mol. Subcell. Biol., 5, 117-143.
5. Kubinyi, H., (2002) Chemical Similarity and Biological Activities J. Brazilian Chem. Soc., 13 (6), 717.
6. Lipkus, A. H.; Yuan, Q.; Lucas, K. A.; Funk, S. A.; Bartelt, W. F., 3rd; Schenck, R. J.; Trippe, A. J. (2008) Structural diversity of organic chemistry. A scaffold analysis of the CAS registry. J. Org. Chem., 73 (12), 4443-51.
7. Fukumura, D.; Jain, R. K. (2007) Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc. Res., 74 (2-3), 72-84.
8. Thorpe, P. E., (2004) Vascular targeting agents as cancer therapeutics. Clin. Cancer Res., 10 (2), 415-27.
9. Folpini, A.; Furfori, P. (1995) Colchicine toxicity - clinical features and treatment. Massive overdose case report. J. Toxicol. Clin. Toxicol., 33 (1), 71-7.
10. Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Calveley, S. B.; Denny, W. A. (1989) Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J. Med. Chem., 32 (4), 793-9.
11. Carlson, R. O., (2008) New tubulin targeting agents currently in clinical development. Exp. Opin. Investig. Drugs, 17 (5), 707-22.
12. Cai, S. X. (2007) Small molecule vascular disrupting agents: Potential new drugs for cancer treatment. Recent Patents Anticancer Drug Discov., 2 (1), 79-101.
13. Brossi, A.; Yeh, H. J.; Chrzanowska, M.; Wolff, J.; Hamel, E.; Lin, C. M.; Quin, F.; Suffness, M.; Silverton, J. (1988) Colchicine and its analogues: Recent findings. Med. Res. Rev., 8 (1), 77-94.
14. Chaplin, D. J.; Pettit, G. R.; Parkins, C. S.; Hill, S. A. (1996) Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br. J. Cancer Suppl., 27, S86-8.
15. Griggs, J.; Metcalfe, J. C.; Hesketh, R. (2001) Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol., 2 (2), 82-7.
16. Davis, P. D.; Dougherty, G. J.; Blakey, D. C.; Galbraith, S. M.; Tozer, G. M.; Holder, A. L.; Naylor, M. A.; Nolan, J.; Stratford, M. R.; Chaplin, D. J.; Hill, S. A. (2002) ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res., 62 (24), 7247-53.
17. Hori, K. (2005) Antineoplastic strategy: Irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy, 51 (6), 357-60.
18. Hokland, S. L.; Horsman, M. R. (2007) The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Int. J. Hyperthermia, 23 (7), 599-606.
19. Lobert, S.; Vulevic, B.; Correia, J. J. (1996) Interaction of vinca alkaloids with tubulin: A comparison of vinblastine, vincristine, and vinorelbine. Biochemistry, 35 (21), 6806-14.
20. Hill, S. A.; Lonergan, S. J.; Denekamp, J.; Chaplin, D. J. (1993) Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur. J. Cancer, 29A (9), 1320-4.
21. Door, R., In Cancer Chemotherapy Handbook, Fritz, Ed. Elsevier publishing Company Inc.: New York, 1980.
22. Holwell, S. E.; Hill, B. T.; Bibby, M. C. (2001) Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br. J. Cancer, 84 (2), 290-5.
23. Kruczynski, A.; Poli, M.; Dossi, R.; Chazottes, E.; Berrichon, G.; Ricome, C.; Giavazzi, R.; Hill, B. T.; Taraboletti, G. (2006) Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur. J. Cancer, 42 (16), 2821-32.
24. Baguley, B. G. S. B. C. Flavones and Xanthenones as Vascular-Disturbing Agents. In Vascular Targeted Terapies in Oncology, Siemann, D. W., Ed. 2006; pp 159-178.
25. Rustin, G. J.; Bradley, C.; Galbraith, S.; Stratford, M.; Loadman, P.; Waller, S.; Bellenger, K.; Gumbrell, L.; Folkes, L.; Halbert, G. (2003) 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br. J. Cancer 88 (8), 1160-7.
26. Segreti, J. A.; Polakowski, J. S.; Koch, K. A.; Marsh, K. C.; Bauch, J. L.; Rosenberg, S. H.; Sham, H. L.; Cox, B. F.; Reinhart, G. A. (2004) Tumor selective antivascular effects of the novel antimitotic compound ABT-751: An in vivo rat regional hemodynamic study. Cancer Chemother. Pharmacol., 54 (3), 273-81.
27. Natsume, T.; Watanabe, J.; Ogawa, K.; Yasumura, K.; Kobayashi, M. (2007) Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy. Cancer Sci., 98 (4), 598-604.
28. Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.; Pervin, A.; Tseng, B.; Carlson, R. O.; Pleiman, C. M., MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res., 67 (12), 5865-71.
29. Nicholson, B.; Lloyd, G. K.; Miller, B. R.; Palladino, M. A.; Kiso, Y.; Hayashi, Y.; Neuteboom, S. T. (2006) NPI-2358 is a tubulin-depolymerizing agent: In-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs, 17 (1), 25-31.
30. Shi, W.; Siemann, D. W. (2005) Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res., 25(6B), 3899-904.
31. Moser, C.; Lang, S. A.; Mori, A.; Hellerbrand, C.; Schlitt, H. J.; Geissler, E. K.; Fogler, W. E.; Stoeltzing, O. (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer, 8, 206.
32. Kelland, L. (2007) Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. Curr. Opin. Mol. Ther., 9(1), 86-91.
33. Ferretti, S.; Allegrini, P. R.; O'Reilly, T.; Schnell, C.; Stumm, M.; Wartmann, M.; Wood, J.; McSheehy, P. M. J. (2005) Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure. Clin. Cancer Res., 11(21), 7773-7784.
34. ter Haar, E.; Rosenkranz, H. S.; Hamel, E.; Day, B. W. (1996) Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorg. Med. Chem., 4(10), 1659-1671.
35. Mabjeesh, N. J.; Escuin, D.; LaVallee, T. M.; Pribluda, V. S.; Swartz, G. M.; Johnson, M. S.; Willard, M. T.; Zhong, H.; Simons, J. W.; Giannakakou, P. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 3(4), 363-75.
36. Kamath, K.; Okouneva, T.; Larson, G.; Panda, D.; Wilson, L.; Jordan, M. A. (2006) 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Mol. Cancer Ther., 5(9), 2225-33.
37. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. (2001) D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res., 61(1), 392-9.
38. von Mehren, M.; Balcerzak, S. P.; Kraft, A. S.; Edmonson, J. H.; Okuno, S. H.; Davey, M.; McLaughlin, S.; Beard, M. T.; Rogatko, A. (2004) Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas. Sarcoma, 8(4), 107-11.
39. Ray, A.; Okouneva, T.; Manna, T.; Miller, H. P.; Schmid, S.; Arthaud, L.; Luduena, R.; Jordan, M. A.; Wilson, L. (2007) Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate. Cancer Res., 67(8), 3767-76.
40. Yokoi, A.; Kuromitsu, J.; Kawai, T.; Nagasu, T.; Sugi, N. H.; Yoshimatsu, K.; Yoshino, H.; Owa, T. (2002) Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol. Cancer Ther., 1(4), 275-86.
41. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chen, C. T.; Chang, J. Y. (2004) BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res., 64(13), 4621-8.
42. Dabydeen, D. A.; Burnett, J. C.; Bai, R.; Verdier-Pinard, P.; Hickford, S. J.; Pettit, G. R.; Blunt, J. W.; Munro, M. H.; Gussio, R.; Hamel, E. (2006) Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol., 70(6), 1866-75.
43. Zask, A.; Kaplan, J.; Musto, S.; Loganzo, F. (2005) Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents. J. Am. Chem. Soc., 127(50), 17667-71.
44. Ayral-Kaloustian, S., Zask, A., Taltobulin. Oncolytic drug, Tubulin polymerization inhibitor, Antimitotic drug. Drugs Future 2005, 30 (3), 254-260.
45. Perez-Melero, C.; Maya, A. B.; del Rey, B.; Pelaez, R.; Caballero, E.; Medarde, M., A new family of quinoline and quinoxaline analogues of combretastatins. Bioorg. Med. Chem. Lett. 2004, 14 (14), 3771-4.
46. Coggiola, B.; Pagliai, F.; Allegrone, G.; Genazzani, A. A.; Tron, G. C. (2005) Synthesis and biological activity of mustard derivatives of combretastatins. Bioorg. Med. Chem. Lett., 15 (15), 3551-4.
47. Alvarez, C.; Alvarez, R.; Corchete, P.; Perez-Melero, C.; Pelaez, R.; Medarde, M. (2007) Synthesis and biological activity of naphthalene analogues of phenstatins: Naphthylphenstatins. Bioorg. Med. Chem. Lett., 17(12), 3417-20.
48. Provot, O.; Giraud, A.; Peyrat, J.-F.; Alami, M.; Brion, J.-D. (2005) Synthetic approach to enyne and enediyne analogues of anticancer agents. Tetrahedron Lett., 46(49), 8547-8550.
49. Sun, L.; Vasilevich, N. I.; Fuselier, J. A.; Hocart, S. J.; Coy, D. H. (2004) Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg. Med. Chem. Lett., 14(9), 2041-6.
50. Medarde, M.; Ramos, A. C.; Caballero, E.; Pelaez-Lamamie de Clairac, R.; Lopez, J. L.; Gravalos, D. G.; Feliciano, A. S. (1999) Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett., 9(16), 2303-8.
51. Hinnen, P.; Eskens, F. A. (2007) Vascular disrupting agents in clinical development. Br. J. Cancer, 96(8), 1159-65.
52. Pan, Q.; Kleer, C. G.; van Golen, K. L.; Irani, J.; Bottema, K. M.; Bias, C.; De Carvalho, M.; Mesri, E. A.; Robins, D. M.; Dick, R. D.; Brewer, G. J.; Merajver, S. D. (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res., 62(17), 4854-9.
53. Dieras, V.; Limentani, S.; Romieu, G.; Tubiana-Hulin, M.; Lortholary, A.; Kaufman, P.; Girre, V.; Besenval, M.; Valero, V. (2008) Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol., 19(7), 1255-60.
54. Sampath, D.; Discafani, C. M.; Loganzo, F.; Beyer, C.; Liu, H.; Tan, X.; Musto, S.; Annable, T.; Gallagher, P.; Rios, C.; Greenberger, L. M. (2003) MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol. Cancer Ther., 2(9), 873-84.
55. Pasquier, E.; Honore, S.; Pourroy, B.; Jordan, M. A.; Lehmann, M.; Briand, C.; Braguer, D. (2005) Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res., 65(6), 2433-40.
56. Vacca, A.; Ribatti, D.; Iurlaro, M.; Merchionne, F.; Nico, B.; Ria, R.; Dammacco, F., Docetaxel versus paclitaxel for antiangiogenesis. J. Hematother. Stem Cell Res., 11(1), 103-18.
57. Polizzi, D.; Pratesi, G.; Monestiroli, S.; Tortoreto, M.; Zunino, F.; Bombardelli, E.; Riva, A.; Morazzoni, P.; Colombo, T.; D'Incalci, M.; Zucchetti, M. (2000) Oral efficacy and bioavailability of a novel taxane. Clin. Cancer Res., 6(5), 2070-4.
58. Petrangolini, G.; Cassinelli, G.; Pratesi, G.; Tortoreto, M.; Favini, E.; Supino, R.; Lanzi, C.; Belluco, S.; Zunino, F. (2004) Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft. Br. J. Cancer, 90(7), 1464-8.
59. Roche, M.; Kyriakou, H.; Seiden, M. (2006) Drug evaluation: Tesetaxel - an oral semisynthetic taxane derivative. Curr. Opin. Investig. Drugs, 7(12), 1092-9.
60. Hennenfent, K. L.; Govindan, R. (2006) Novel formulations of taxanes: A review. Old wine in a new bottle? Ann. Oncol. 17(5), 735-49.
61. Fumoleau, P.; Coudert, B.; Isambert, N.; Ferrant, E. (2007) Novel tubulin-targeting agents: Anticancer activity and pharmacologic profile of epothilones and related analogues. Ann. Oncol., [x 18 x] Suppl 5, v9-15.
62. Hoffmann, J.; Vitale, I.; Buchmann, B.; Galluzzi, L.; Schwede, W.; Senovilla, L.; Skuballa, W.; Vivet, S.; Lichtner, R. B.; Vicencio, J. M.; Panaretakis, T.; Siemeister, G.; Lage, H.; Nanty, L.; Hammer, S.; Mittelstaedt, K.; Winsel, S.; Eschenbrenner, J.; Castedo, M.; Demarche, C.; Klar, U.; Kroemer, G. (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res., 68(13), 5301-8.
63. James, M. L.; Maxwell, P. J.; Catherine, T. A.; Brian, M. G.; Jessica, L. T.; John, R.; Paul, M.; Yi-Zarn, W.; Eugene, A. W. (2004) Epothilone B is a more potent antiangiogenic than paclitaxel in a human tumor-based angiogenesis model. J. Am. College Surg., 199(3), 90.
64. Altmann, K. H.; Gertsch, J. (2007) Anticancer drugs from nature - natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep., 24(2), 327-57.
65. Rizvi, N.; Villalona-Calero, M.; Lynch, T.; Yee, L.; Gabrail, N.; Sandler, A.; Cropp, G.; Graham, M.; Palmer, G. (2005) P-565 A Phase II study of KOS-862 (Epothilone D) as second-linetherapy in non-small cell lung cancer. Lung Cancer, 49(Supplement 2), S266-S267.
66. Cho, Y. S.; Wu, K.-D.; Moore, M. A. S.; Chou, T.-C.; Danishefsky, S. J., Second generation epothilones: Discovery of fludelone and its extraordinary antitumor properties. 2005, 30 (7), 737.
67. Lee, F. Y.; Borzilleri, R.; Fairchild, C. R.; Kim, S. H.; Long, B. H.; Reventos-Suarez, C.; Vite, G. D.; Rose, W. C.; Kramer, R. A. (2001) BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res., 7(5), 1429-37.
68. Britten, C. D. (2004) Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. Mol. Cancer Ther., 3(10), 1335-42.
69. Jani, J. P.; Finn, R. S.; Campbell, M.; Coleman, K. G.; Connell, R. D.; Currier, N.; Emerson, E. O.; Floyd, E.; Harriman, S.; Kath, J. C.; Morris, J.; Moyer, J. D.; Pustilnik, L. R.; Rafidi, K.; Ralston, S.; Rossi, A. M.; Steyn, S. J.; Wagner, L.; Winter, S. M.; Bhattacharya, S. K. (2007) Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res., 67(20), 9887-93.
70. Bradley, D. P.; Tessier, J. L.; Checkley, D.; Kuribayashi, H.; Waterton, J. C.; Kendrew, J.; Wedge, S. R. (2008) Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: An investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR Biomed., 21(1), 42-52.
71. Rocha-Lima, C. M.; Soares, H. P.; Raez, L. E.; Singal, R. (2007) EGFR targeting of solid tumors. Cancer Control, 14(3), 295-304.
72. Ayers, M.; Fargnoli, J.; Lewin, A.; Wu, Q.; Platero, J. S. (2007) Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res., 67 (14), 6899-906.
73. Vultur, A.; Buettner, R.; Kowolik, C.; Liang, W.; Smith, D.; Boschelli, F.; Jove, R. (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther., 7(5), 1185-94.
74. Jefford, M.; Zalcberg, J. (2005) Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer. Am. J. Cancer, 4(1), 14-34.
75. Rabindran, S. K.; Discafani, C. M.; Rosfjord, E. C.; Baxter, M.; Floyd, M. B.; Golas, J.; Hallett, W. A.; Johnson, B. D.; Nilakantan, R.; Overbeek, E.; Reich, M. F.; Shen, R.; Shi, X.; Tsou, H. R.; Wang, Y. F.; Wissner, A. (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res., 64(11), 3958-65.
76. Koyama, N.; Magario, N.; Yamamoto, Y.; Matsui, J.; Tsuruoka, A. (2008) [Anti-tumor effect of E7080, a novel angiogenesis inhibitor]. Nippon Yakurigaku Zasshi, 132(2), 100-4.
77. Schmidt, M.; Bastians, H. (2007) Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Drug Resist. Updat, 10(4-5), 162-81.
78. Beyer, C. F.; Zhang, N.; Hernandez, R.; Vitale, D.; Lucas, J.; Nguyen, T.; Discafani, C.; Ayral-Kaloustian, S.; Gibbons, J. J. (2008) TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res., 68(7), 2292-300.
79. Kling, J. (2006) Bundling next-generation cancer therapies for synergy. Nat. Biotechnol., 24(8), 871-2.
80. Cabebe, E.; Wakelee, H. (2007) Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr. Treat Options Oncol., 8(1), 15-27.
81. Kamei, S.; Okada, H.; Inoue, Y.; Yoshioka, T.; Ogawa, Y.; Toguchi, H. (1993) Antitumor effects of angiogenesis inhibitor TNP-470 in rabbits bearing VX-2 carcinoma by arterial administration of microspheres and oil solution. J. Pharmacol. Exp. Ther., 264(1), 469-74.
82. Folkman, J. (2007) Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov., 6(4), 273-86.
83. Ning, S.; Laird, D.; Cherrington, J. M.; Knox, S. J. (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat. Res., 157 (1), 45-51.
84. Kim, S.; Yazici, Y. D.; Calzada, G.; Wang, Z. Y.; Younes, M. N.; Jasser, S. A.; El-Naggar, A. K.; Myers, J. N. (2007) Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther., 6(6), 1785-92.
85. Liu, X.; Yao, W.; Newton, R. C.; Scherle, P. A. (2008) Targeting the c-MET signaling pathway for cancer therapy. Exp. Opin. Investig. Drugs, 17(7), 997-1011.
86. Albert, D. H.; Tapang, P.; Magoc, T. J.; Pease, L. J.; Reuter, D. R.; Wei, R. Q.; Li, J.; Guo, J.; Bousquet, P. F.; Ghoreishi-Haack, N. S.; Wang, B.; Bukofzer, G. T.; Wang, Y. C.; Stavropoulos, J. A.; Hartandi, K.; Niquette, A. L.; Soni, N.; Johnson, E. F.; McCall, J. O.; Bouska, J. J.; Luo, Y.; Donawho, C. K.; Dai, Y.; Marcotte, P. A.; Glaser, K. B.; Michaelides, M. R.; Davidsen, S. K. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther., 5(4), 995-1006.
87. Hotz, H. G.; Reber, H. A.; Hotz, B.; Sanghavi, P. C.; Yu, T.; Foitzik, T.; Buhr, H. J.; Hines, O. J. (2001) Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J. Gastrointest. Surg. 5(2), 131-8.
88. Kim, J. H.; Lee, S. K.; Ki, M. H.; Choi, W. K.; Ahn, S. K.; Shin, H. J.; Hong, C. I. (2004) Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin. Int. J. Pharm., 272(1-2), 79-89.
89. Moutouh-de Parseval, L. A.; Verhelle, D.; Glezer, E.; Jensen-Pergakes, K.; Ferguson, G. D.; Corral, L. G.; Morris, C. L.; Muller, G.; Brady, H.; Chan, K. (2008) Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest., 118(1), 248-58.
90. Kumar, S.; Rajkumar, S. V. (2006) Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur. J. Cancer, 42(11), 1612-22.
91. Burke, P. A.; DeNardo, S. J.; Miers, L. A.; Lamborn, K. R.; Matzku, S.; DeNardo, G. L. (2002) Cilengitide targeting of alpha (v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res., 62(15), 4263-72.
92. Usui, T.; Kondoh, M.; Cui, C. B.; Mayumi, T.; Osada, H. (1998) Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochem. J., 333(Pt 3), 543-8.
93. Graff, J. R.; McNulty, A. M.; Hanna, K. R.; Konicek, B. W.; Lynch, R. L.; Bailey, S. N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J. E.; Sams, L.; Huss, K. L.; Campbell, R. M.; Iversen, P. W.; Neubauer, B. L.; Brown, T. J.; Musib, L.; Geeganage, S.; Thornton, D. (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res., 65(16), 7462-9.
94. Martiny-Baron, G.; Fabbro, D. (2007) Classical PKC isoforms in cancer. Pharmacol. Res., 55(6), 477-86.
95. Utz, I.; Gekeler, V.; Ise, W.; Beck, J.; Spitaler, M.; Grunicke, H.; Hofmann, J. (1996) Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines. Anticancer Res., 16(1), 289-96.
96. Sharma, S.; Freeman, B.; Turner, J.; Symanowski, J.; Manno, P.; Berg, W.; Vogelzang, N. (2008) A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors. Invest. New Drugs.
97. Sherman, S. I.; Wirth, L. J.; Droz, J. P.; Hofmann, M.; Bastholt, L.; Martins, R. G.; Licitra, L.; Eschenberg, M. J.; Sun, Y. N.; Juan, T.; Stepan, D. E.; Schlumberger, M. J. (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl. J. Med., 359(1), 31-42.
98. Choueiri, T. K. (2008) Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr. Opin. Investig. Drugs, 9(6), 658-71.
99. Ribatti, D.; Raffaghello, L.; Marimpietri, D.; Cosimo, E.; Montaldo, P. G.; Nico, B.; Vacca, A.; Ponzoni, M. (2003) Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett., 197(1-2), 181-4.
100. Moasser, M. M. (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene, 26(46), 6577-92.
101. Funahashi, Y.; Sugi, N. H.; Semba, T.; Yamamoto, Y.; Hamaoka, S.; Tsukahara-Tamai, N.; Ozawa, Y.; Tsuruoka, A.; Nara, K.; Takahashi, K.; Okabe, T.; Kamata, J.; Owa, T.; Ueda, N.; Haneda, T.; Yonaga, M.; Yoshimatsu, K.; Wakabayashi, T. (2002) Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res., 62(21), 6116-23.
102. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P. P.; Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J. G. (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res., 67(9), 4408-17.
103. Dalrymple, S. L.; Becker, R. E.; Isaacs, J. T. (2007) The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate, 67(7), 790-7.
104. Million, R. P. (2008) Therapeutic area crossroads: Anti-angiogenesis. Nat. Rev. Drug Discov., 7(2), 115-116.
105. Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R. K. (2002) Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature, 416(6878), 279-80.
106. Bock, F.; Onderka, J.; Dietrich, T.; Bachmann, B.; Kruse, F. E.; Paschke, M.; Zahn, G.; Cursiefen, C. (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest. Ophthalmol. Vis. Sci., 48(6), 2545-52.
107. Pegaptanib sodium (Macugen) for macular degeneration. Med. Lett., Drugs Ther., 47 (1212), 55-6.
108. Zhu, W. H.; Guo, X.; Villaschi, S.; Francesco Nicosia, R. (2000) Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Invest., 80(4), 545-55.
109. Ferrario, A.; Chantrain, C. F.; von Tiehl, K.; Buckley, S.; Rucker, N.; Shalinsky, D. R.; Shimada, H.; DeClerck, Y. A.; Gomer, C. J. (2004) The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res., 64(7), 2328-32.
110. Dupont, E.; Falardeau, P.; Mousa, S. A.; Dimitriadou, V.; Pepin, M. C.; Wang, T.; Alaoui-Jamali, M. A. (2002) Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin. Exp. Metastasis, 19(2), 145-53.
111. Medici, V.; Sturniolo, G. C. (2008) Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications. IDrugs, 11(8), 592-606.
112. Juarez, J. C.; Betancourt, O., Jr.; Pirie-Shepherd, S. R.; Guan, X.; Price, M. L.; Shaw, D. E.; Mazar, A. P.; Donate, F. (2006) Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin. Cancer Res., 12(16), 4974-82.
113. Brem, S.; Grossman, S. A.; Carson, K. A.; New, P.; Phuphanich, S.; Alavi, J. B.; Mikkelsen, T.; Fisher, J. D. (2005) Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neurooncology, 7(3), 246-53.
114. Moriguchi, M.; Nakajima, T.; Kimura, H.; Watanabe, T.; Takashima, H.; Mitsumoto, Y.; Katagishi, T.; Okanoue, T.; Kagawa, K. (2002) The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int. J. Cancer, 102(5), 445-52.
115. Sparano, J. A.; Gray, R.; Giantonio, B.; O'Dwyer, P.; Comis, R. L. (2004) Evaluating antiangiogenesis agents in the clinic: The eastern cooperative oncology group portfolio of clinical trials. Clin. Cancer Res., 10(4), 1206-11.
116. Ferlini, C.; Gallo, D.; Scambia, G. (2008) New taxanes in development. Exp. Opin. Investig. Drugs, 17(3), 335-47.
117. Donovan, D.; Vahdat, L. T. (2008) Epothilones: Clinical update and future directions. Oncology (Williston Park), 22(4), 408-16; discussion 416, 421, 424 passim.
118. Gaya, A. M.; Rustin, G. J. (2005)Vascular disrupting agents: A new class of drug in cancer therapy. Clin. Oncol. (R. Coll. Radiol.), 17(4), 277-90.
119. Horsman, M. R.; Siemann, D. W. (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res., 66(24), 11520-39.
120. Siemann, D. W.; Shi, W. (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys., 60(4), 1233-40.
121. Cooney, M. M.; van Heeckeren, W.; Bhakta, S.; Ortiz, J.; Remick, S. C. (2006) Drug insight: Vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat. Clin. Pract. Oncol., 3(12), 682-92.
122. Hait, W. N.; Rubin, E.; Alli, E.; Goodin, S., Tubulin Targeting Agents. 2007, 2 (1), 1-18.
123. Pellegrini, F.; Budman, D. R. (2005) Review: Tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest., 23(3), 264-73.
124. Sengupta, S.; Thomas, S. A. (2006) Drug target interaction of tubulin-binding drugs in cancer therapy. Exp. Rev. Anticancer Ther., 6(10), 1433-47.
125. Hadfield, J. A.; Ducki, S.; Hirst, N.; McGown, A. T. (2003) Tubulin and microtubules as targets for anticancer drugs. Prog. Cell Cycle Res., 5, 309-25.
126. Correia, J. J.; Lobert, S. (2001) Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des., 7(13), 1213-28.
127. Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. (2002) The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol., 83(1), 21-38.
128. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. (2005) A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J. Med. Chem., 48(19), 6107-16.
129. Laura K. Shawver, k. E. L., T. Anne T. Fong, Gerald McMahon, Greg D. Plowman, Laurie M. Strawn. Drug Discov. Today, 1997, 2 (2), 50-63.
130. Kim, D. W.; Lu, B.; Hallahan, D. E. (2004) Receptor tyrosine kinase inhibitors as anti-angiogenic agents. Curr. Opin. Investig. Drugs, 5(6), 597-604.
131. Kerbel, R.; Folkman, J. (2002) Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer, 2(10), 727-39.
132. Nicholson, R. I.; Gee, J. M.; Harper, M. E. (2001) EGFR and cancer prognosis. Eur. J. Cancer, 37 Suppl 4, S9-15.
133. Eskens, F. A. (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br. J. Cancer, 90(1), 1-7.
134. Qian, D. Z.; Wang, X.; Kachhap, S. K.; Kato, Y.; Wei, Y.; Zhang, L.; Atadja, P.; Pili, R. (2004) The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res., 64(18), 6626-34.
135. Fujita, K.; Asami, Y.; Tanaka, K.; Akita, M.; Merker, H. J. (2004) Anti-angiogenic effects of thalidomide: Expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta. Histochem. Cell Biol., 122(1), 27-33.
136. Brewer, G. J. (2001) Copper control as an antiangiogenic anticancer therapy: Lessons from treating Wilson's disease. Exp. Biol. Med. (Maywood), 226(7), 665-73.
137. Sun, L.; McMahon, G. (2000) Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Discov. Today, 5(8), 344-353.
138. Giannakakou, P.; Gussio, R.; Nogales, E.; Downing, K. H.; Zaharevitz, D.; Bollbuck, B.; Poy, G.; Sackett, D.; Nicolaou, K. C.; Fojo, T. (2000)A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA, 97(6), 2904-9.
139. Waldman, A.; Kritharides, L. (2003) The pleiotropic effects of HMG-CoA reductase inhibitors: Their role in osteoporosis and dementia. Drugs, 63(2), 139-52.
140. Mahadevan, V.; Malik, S. T.; Meager, A.; Fiers, W.; Lewis, G. P.; Hart, I. R. (1990) Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res., 50(17), 5537-42.
141. Pang, J. H.; Cao, Z.; Joseph, W. R.; Baguley, B. C.; Ching, L. M. (1998) Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor. Eur. J. Cancer, 34(8), 1282-9.
142. Yee, K. W.; Hagey, A.; Verstovsek, S.; Cortes, J.; Garcia-Manero, G.; O'Brien, S. M.; Faderl, S.; Thomas, D.; Wierda, W.; Kornblau, S.; Ferrajoli, A.; Albitar, M.; McKeegan, E.; Grimm, D. R.; Mueller, T.; Holley-Shanks, R. R.; Sahelijo, L.; Gordon, G. B.; Kantarjian, H. M.; Giles, F. J. (2005) Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res., 11(18), 6615-24.
143. Vacca, A.; Iurlaro, M.; Ribatti, D.; Minischetti, M.; Nico, B.; Ria, R.; Pellegrino, A.; Dammacco, F. (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood, 94 (12), 4143-55.